Clinical trial
A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus (APRICITY-B)
NCT06100952 is registered in ClinicalTrials.gov with Epion Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus (APRICITY-B)
- Lead sponsor
- Epion Therapeutics
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 1, 2023
- Completion date
- March 17, 2026
- Enrollment
- 398 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.